Seattle Genetics Plans To Increase the Production of Cancer Drugs

The Bothell-based biotechnology company, Seattle Genetics has revealed its plans to increase its drug pipeline as well as its workforce. According to an article published in the Bizjournals.com, the rapidly growing cancer drug producer plans to increase the reach of its commercialized drug, Adcetris. The firm also plans to hire 100 employees in the United States and 20 in its office based in Switzerland. This comes after the company already hired 800 employees this year to assist in its research programs.

Seattle Genetics has partnered with Takeda Pharmaceutical Company Ltd, one of the top 15 pharmaceutical firms in the world in the commercialization of Adcetris. Seattle Genetics has rights to commercialize the drug in the United States and Canada while Takeda has exclusive rights in all other countries.

The firm is carrying out a comprehensive clinical development program to analyze the potential of using the treatment for CD30-expressing lymphomas such as cutaneous T-cell lymphoma and Hodgkin lymphoma. Phase 3 trials have already started to determine the viability of treating Hodgkin lymphoma using Adcetris. The firm also hopes to unveil 12 other new drugs in their class of ADCs. Among the drugs that are on trials are drugs for treating breast and bladder cancer and 33A for treating acute myeloid leukemia.

Seattle Genetics was founded in 1998 by Clay Siegall who serves as its president and chief executive officer. Dr. Siegall is a scientist by profession and emphasizes on developing innovative treatment for cancer. Under the leadership of Dr. Siegall, Seattle Genetics is producing a huge portfolio of clinical and preclinical drugs aimed at treating various types of cancer and different unmet medical conditions.

Dr. Siegall has helped the company to enter into several strategic licenses for its ADC technology that has generated over $325 million. The scientist has also led the firm’s capital raising programs, securing more than $1.2 billion through private and public funding.

Besides overseeing activities of his firm, Dr. Siegall serves on the board of directors of Mirna Therapeutics, Washington Roundtable, Ultragenyx Pharmaceutical and Alder BioPharmaceuticals. His work received various recognitions such as the 2013 University of Maryland Alumnus of the Year for Math, Computer, and Natural Sciences. Dr. Siegall studied Zoology at the University of Maryland and holds a Ph.D. in Genetics from George Washington University.